新型氟萘啶酮LB20304的体外和体内评价
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
作者信息
Oh J I, Paek K S, Ahn M J, Kim M Y, Hong C Y, Kim I C, Kwak J H
机构信息
Biotech Research Institute, LG Chemical Ltd., Taejon, Korea.
出版信息
Antimicrob Agents Chemother. 1996 Jun;40(6):1564-8. doi: 10.1128/AAC.40.6.1564.
Abstract
In vitro activity of LB20304 against 1,231 clinical isolates was evaluated and compared with those of ciprofloxacin, sparfloxacin, lomefloxacin, and ofloxacin. LB20304 demonstrated the most potent activity against gram-positive bacteria. It was 32- to 64-fold more active than ciprofloxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus, methicillin-resistant Staphylococcus epidermidis, and Streptococcus pneumoniae (penicillin G resistant). LB20304 was also highly active against most members of the family Enterobacteriaceae. Its activity was more potent than those of sparfloxacin, ofloxacin, and lomefloxacin and comparable to that of ciprofloxacin. The protective activities of LB20304 against systemic infections caused by gram-positive bacteria in mice were superior to those of ciprofloxacin and sparfloxacin. Against infections by gram-negative bacteria, LB20304 was slightly less active than ciprofloxacin.
摘要
评估了LB20304对1231株临床分离株的体外活性，并与环丙沙星、司帕沙星、洛美沙星和氧氟沙星进行了比较。LB20304对革兰氏阳性菌表现出最强的活性。它对甲氧西林敏感金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌、耐甲氧西林表皮葡萄球菌和肺炎链球菌（耐青霉素G）的活性比环丙沙星高32至64倍。LB20304对肠杆菌科的大多数成员也具有高活性。其活性比司帕沙星、氧氟沙星和洛美沙星更强，与环丙沙星相当。LB20304对小鼠革兰氏阳性菌引起的全身感染的保护活性优于环丙沙星和司帕沙星。对于革兰氏阴性菌感染，LB20304的活性略低于环丙沙星。
相似文献
1
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
Antimicrob Agents Chemother. 1996 Jun;40(6):1564-8. doi: 10.1128/AAC.40.6.1564.
2
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
Antimicrob Agents Chemother. 1997 Jan;41(1):204-11. doi: 10.1128/AAC.41.1.204.
3
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Diagn Microbiol Infect Dis. 2001 May-Jun;40(1-2):51-7. doi: 10.1016/s0732-8893(01)00241-3.
4
Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
Eur J Clin Microbiol Infect Dis. 2001 Nov;20(11):814-9. doi: 10.1007/s100960100604.
5
Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
Diagn Microbiol Infect Dis. 2001 Aug;40(4):187-92. doi: 10.1016/s0732-8893(01)00271-1.
6
In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic.
Antimicrob Agents Chemother. 2002 Sep;46(9):3071-4. doi: 10.1128/AAC.46.9.3071-3074.2002.
7
Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
Clin Microbiol Infect. 2001 Sep;7(9):499-503. doi: 10.1046/j.1198-743x.2001.00297.x.
8
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
J Antimicrob Chemother. 1997 Sep;40(3):427-31. doi: 10.1093/jac/40.3.427.
9
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
Diagn Microbiol Infect Dis. 1999 Feb;33(2):87-91. doi: 10.1016/s0732-8893(98)00104-7.
10
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
J Antimicrob Chemother. 1998 Feb;41(2):223-9. doi: 10.1093/jac/41.2.223.
引用本文的文献
1
NHC-BIAN-Cu(I)-Catalyzed Friedländer-Type Annulation of 2-Amino-3-(per)fluoroacetylpyridines with Alkynes on Water.
J Org Chem. 2022 May 6;87(9):6115-6136. doi: 10.1021/acs.joc.2c00380. Epub 2022 Apr 8.
2
A Validated Reverse Phase-Ultra-Performance Liquid Chromatography Method for the Determination of Gemifloxacin Mesylate in Bulk and its Pharmaceutical Preparation.
Turk J Pharm Sci. 2019 Mar;16(1):8-13. doi: 10.4274/tjps.04934. Epub 2018 Dec 31.
3
Ion-pair spectrophotometric estimation of gemifloxacin.
Pharm Methods. 2012 Jan;3(1):26-30. doi: 10.4103/2229-4708.97713.
4
Two validated spectrofluorometric methods for determination of gemifloxacin mesylate in tablets and human plasma.
Int J Anal Chem. 2013;2013:137279. doi: 10.1155/2013/137279. Epub 2013 May 16.
5
Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.
Int J Pharm. 2011 Nov 25;420(1):26-33. doi: 10.1016/j.ijpharm.2011.08.009. Epub 2011 Aug 16.
6
In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.
Antimicrob Agents Chemother. 2006 Jun;50(6):2261-4. doi: 10.1128/AAC.01407-05.
7
Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Antimicrob Agents Chemother. 2002 Feb;46(2):413-9. doi: 10.1128/AAC.46.2.413-419.2002.
8
In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.
Antimicrob Agents Chemother. 2001 Sep;45(9):2486-94. doi: 10.1128/AAC.45.9.2486-2494.2001.
9
Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.
Antimicrob Agents Chemother. 2001 Feb;45(2):540-5. doi: 10.1128/AAC.45.2.540-545.2001.
10
Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes.
Antimicrob Agents Chemother. 2000 Nov;44(11):3193-5. doi: 10.1128/AAC.44.11.3193-3195.2000.
本文引用的文献
1
Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1- pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy.
J Med Chem. 1993 Apr 2;36(7):871-82. doi: 10.1021/jm00059a012.
2
New quinolones and gram-positive bacteria.
Antimicrob Agents Chemother. 1994 Feb;38(2):163-9. doi: 10.1128/AAC.38.2.163.
3
Structure-activity and structure-side-effect relationships for the quinolone antibacterials.
J Antimicrob Chemother. 1994 Apr;33(4):685-706. doi: 10.1093/jac/33.4.685.
4
Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids.
J Med Chem. 1988 May;31(5):983-91. doi: 10.1021/jm00400a016.
5
Quinolones in the treatment of lower respiratory tract infections.
Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S1212-9. doi: 10.1093/clinids/11.supplement_5.s1212.
6
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.
Antimicrob Agents Chemother. 1990 Nov;34(11):2050-4. doi: 10.1128/AAC.34.11.2050.
7
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Antimicrob Agents Chemother. 1991 Apr;35(4):764-6. doi: 10.1128/AAC.35.4.764.
8
Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.
J Infect Dis. 1991 Jun;163(6):1279-85. doi: 10.1093/infdis/163.6.1279.
9
Mechanisms of fluoroquinolone resistance in Staphylococcus aureus.
J Infect Dis. 1991 May;163(5):1080-6. doi: 10.1093/infdis/163.5.1080.
10
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.
Antimicrob Agents Chemother. 1992 Jul;36(7):1491-8. doi: 10.1128/AAC.36.7.1491.
Zotero 插件